Table 4.
Biological and clinical characteristics of the 83 AML patients included in the study.
| Patient Characteristics, Cell Morphology | Disease Etiology, Cell Morphology | Cell Genetics | |||
|---|---|---|---|---|---|
| Age | De novo AML 1 | 55 | Cytogenetics | ||
| Median (yrs) | 66 | Favorable | 7 | ||
| Range (yrs) | 18–92 | Secondary AML | Intermediate | 14 | |
| MDS | 12 | Normal | 38 | ||
| Gender | CMML | 4 | Adverse | 14 | |
| Females | 39 | CML | 1 | n.d. | 10 |
| Males | 44 | CLL | 1 | ||
| MF | 4 | Flt3 mutations 3 | |||
| FAB classification | PV | 1 | ITD | 26 | |
| M0 | 5 | Chemotherapy | 1 | Wild-type | 41 |
| M1 | 20 | n.d. | 16 | ||
| M2 | 14 | AML relapse 2 | 7 | ||
| M4 | 21 | NPM1 mutations | |||
| M5 | 17 | CD34 receptor | Mutated | 22 | |
| n.d. | 6 | Negative (≤20%) | 25 | Wild-type | 45 |
| Positive (>20%) | 50 | n.d. | 16 | ||
| n.d. | 8 | ||||
1 Patients that were enrolled twice, at first diagnosis and relapse, are listed with their de novo characteristics. 2 Three of the patients had relapse of secondary AML. 3 One patient in each group has a point mutation at D835. n.d.: not determined. Abbreviations: MDS: myelodysplastic syndrome; CMML: chronic myelomonocytic leukemia; CML: chronic myeloid leukemia; CLL: chronic lymphocytic leukemia; MF: myelofibrosis; PV: polycytemia vera; ITD: internal tandem repeat; n.d.: not determined.